ExploRNA Therapeutics och Łukasiewicz - IChP inleder partnerskap för att främja GMP-tillverkning av mRNA-kap-analoger
ExploRNA Therapeutics och Łukasiewicz - IChP har ingått ett strategiskt partnerskap för att förbättra GMP-tillverkningen av nästa generations mRNA-kap-analoger. Samarbetet syftar till att påskynda utvecklingen av nya terapier.
Biotechnology company ExploRNA Therapeutics and the Łukasiewicz Research Network – Industrial Chemistry Institute (Łukasiewicz - IChP) have entered into a strategic partnership aimed at advancing the Good Manufacturing Practice (GMP) production of next-generation mRNA cap analogs.
The collaboration seeks to scale up the manufacturing process for these crucial mRNA components, which are essential for the development of novel therapeutics. ExploRNA Therapeutics specializes in mRNA capping technologies, while Łukasiewicz - IChP brings expertise in industrial chemistry and manufacturing.
This partnership is expected to accelerate the translation of research findings into clinical applications. By ensuring a reliable and scalable GMP-compliant supply of mRNA cap analogs, the companies aim to facilitate the development of new mRNA-based drugs and vaccines.
The agreement highlights the growing importance of specialized manufacturing capabilities in the biotechnology sector, particularly for advanced therapies like those based on mRNA technology.